- Home
- ABVC vs CING Comparison
ABVC vs CING Comparison
Compare ABVC & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | CING |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 40.5M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABVC | CING |
|---|---|---|
| Price | $1.47 | $7.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 48.5K | ★ 313.0K |
| Earning Date | 06-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $509,589.00 | N/A |
| Revenue This Year | $735.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $3.20 |
| 52 Week High | $4.02 | $7.92 |
Technical Indicators
Market Signals| Indicator | ABVC | CING |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 67.38 |
| Support Level | $1.15 | $3.58 |
| Resistance Level | $1.52 | $7.92 |
| Average True Range (ATR) | 0.12 | 0.50 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 56.63 | 95.37 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.